SPAC Presentation

Leading Pharmaceutical Integral CDMO Specialized in Softgels A Preferred Supplier to the Global Pharmaceutical Companies Business Model Features ■ ■ ■ 5-10-year contracts; -70% of which are US$-denominated Over 126 clients in more than 32 countries; strong US presence Over 639 SKUs across ~300 product lines 86% of B2B sales are linked to Procaps' own technologies and intellectual property Selected Procaps Partners Abbott Selected CDMO Players¹ EV/EBITDA 2021E Multiple 2020-2022E Net Revenue Growth / 2020 EBITDA Margin Softi Sel inca BAUSCH- Health 2 Patheon ³ Recipharm4 13% / 24% gsk 20.4x 5% / 18% 17.0x 49% / 18% Consort 13.7x Medical5 -8% / 15% Pfizer Catalent Siegfried Lonza Cambrex6 BAYER BAYER Soft capsules comparables 17.3x 18% / 24% 17.7x 18% / 17% 28.4x -6% / 28% 16.7x -2% / 27% SANOFI PROCAPS GROUP Source: Procaps; Capital IQ as of May 14th, 2021 Note: (1) Data as of May 14th, 2021; (2) Softigel 2020E-2022E Revenue Growth and 2021E EBITDA Margin are based on adjusted Company projections. Softgel's EBITDA margin is an estimated considering the allocation of a % of total indirect expenses; (3) EV refers to transaction value as per announcement, Revenue growth is Q117 LTM, EV/EBITDA calculated as transaction value over EBITDA Q117 LTM, and EBITDA margin calculated with Q117 LTM figures; (4) EV refers to transaction value as per announcement, EV/EBITDA calculated as transaction value over 2020 Adj. EBITDA, Revenue growth is 2019-2020, and EBITDA margin calculated with 2020 figures; (5) EV refers to transaction value as per announcement, EV/EBITDA calculated as transaction value over 3Q19 LTM EBITDA, Revenue growth is 3Q19 LTM, and EBITDA margin calculated with 3Q19 LTM figures; (6) EV refers to transaction value as per announcement, EV/EBITDA calculated as transaction value over 2Q19 LTM EBITDA, Revenue growth is 2Q19 LTM, and EBITDA margin calculated with 2Q19 LTM figures ..:: 23

View entire presentation